Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded Best Biotech Pipeline
at the World Orphan Drug Congress in Geneva. The award recognises the size and
range of Sobi's orphan pipeline and also the mix across designation and
authorisation phases within the portfolio. The judging panel also acknowledged
Sobi's long-term future as well as the company's pioneering development approach
and commitment to the rare disease and orphan drug space.
"We are truly honoured by this recognition", said Geoffrey McDonough, CEO at
Sobi. "In our work to create a more hopeful future for patients with rare
diseases we are also seeking new models for the development of orphan drugs."
Sobi was also recognized as part of the DevelopAKUre Consortium, which was
awarded the Best European Industry - Patient Organisation Collaboration award.
DevelopAKUre is a clinical trial programme for the drug nitisinone (Orfadin®),
the first potential treatment for Alkaptonuria (AKU). It is made up of 13
hospitals, a pharmaceutical company, consultancies, universities, biotech
companies and national AKU patient groups.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(? 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information - not
for publication
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress:
http://hugin.info/134557/R/1744773/587143.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1744773]
Unternehmensinformation / Kurzprofil:
Datum: 21.11.2013 - 08:30 Uhr
Sprache: Deutsch
News-ID 319040
Anzahl Zeichen: 3201
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
